{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-004971","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.009758+00:00","generated_at":"2026-05-26T14:17:28.427009+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Galectin reports 68.1% reduction in new varices with belapectin in U.S. patients from NAVIGATE trial","bullets":["Per-protocol U.S. patients (n=186): 68.1% reduction in new varices with belapectin 2 mg vs placebo (p=0.02).","New prevalence estimate: ~3 million U.S. adults with MASH cirrhosis and clinically significant portal hypertension.","Top-line composite endpoint missed statistical significance in ITT (N=355); completer analysis had 49.3% reduction (p=0.04 revised).","Full analysis ongoing; additional 36-month data expected by end of Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-004971","json":"https://secwatch.observer/filing/0001140361-25-004971.json","markdown":"https://secwatch.observer/filing/0001140361-25-004971.md","text":"https://secwatch.observer/filing/0001140361-25-004971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125004971/0001140361-25-004971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125004971/ny20043588x1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T14:17:28.427009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}